Cochrane Review: Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer

Zusammenfassung

Einsatz von Next‐Generation‐Sequenzierung zur Optimierung zielgerichteter Therapien bei Menschen mit rezidiviertem oder metastasiertem Krebs - Kazmi, F - 2025 \| Cochrane Library [Skip to Content](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014872.pub2/full/de#main-content) [Close cookies message](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014872.pub2/full/de#) Cookies Our site uses cookies to improve your experience. You can find out more about our use of co

Kerninformationen

doi/10.1002/14651858.CD014872.pub2/full/de#) [Cochrane Database of Systematic reviews](https://www.cochranelibrary.com/en/about/about-cochrane-reviews) Review - Intervention Collapse all Expand all ## Abstract available in ### Background Matched targeted therapies (MTT) given alone or in comb...

y. As a result, next‐generation sequencing testing of recurrent or late‐stage disease is discouraged. We lack evidence to support the utility of next generation sequencing in guiding matched targeted therapies in this setting. ### Objectives To evaluate the benefits and harms of matched targeted t...

ed trials (RCTs) that had enroled participants with advanced/refractory solid or haematological cancers who had progressed through at least one line of standard anti‐cancer systemic therapy. To be eligible, all participants should have received matched targeted therapy based on next‐generation seque...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen